Can Gene Therapy Help the Heart Regrow

A cut in your skin heals, and you rarely send the cells a thank-you note. A heart attack poses a different problem. Lost heart muscle is difficult to replace; scar stabilizes the damaged area while surviving muscle works harder. Life may continue with a weakened pump. Understandably, researchers would like to persuade surviving heart cells to make replacements. The tricky part is giving them enough encouragement without launching a construction project nobody knows how to stop.

The premise is not that the adult heart has absolutely no renewal. Studies using carbon dating of cellular DNA found that human heart muscle cells turn over slowly, with renewal declining with age. The problem is scale: this limited replacement cannot normally make up for the substantial loss caused by a major heart attack.[1]

The Texas Heart Institute at Baylor College of Medicine is participating in SALVADOR-HF, an early human trial of YAP101 for ischemic heart failure. This is an effort to test a regenerative strategy, not evidence that regeneration has already been achieved in patients. The registered study's principal task is to assess safety and dose.[2]

Releasing a growth brake

Cells need permission to grow, and they also need ways to be told that they have done enough. Too little replacement leaves injury unrepaired. Too much or poorly organized growth creates its own problems. The Hippo signaling pathway helps regulate this balance by limiting proteins including YAP that promote growth-related programs. The name sounds endearingly zoological. The task is less cuddly: restraining growth without making useful repair impossible.

The treatment's appeal comes from that tension. A brake that protects tissue from excessive growth can also limit regeneration after injury. Loosening it might help, but location and timing become crucial. We are adjusting a system whose restraint usually has a purpose. Calling a protein a "brake" explains part of its role; it does not tell us how far to release it or what the heart will do next.

YAP101 targets a component of this system called SAV1, short for Salvador. It uses an adeno-associated viral vector to deliver instructions for a small hairpin RNA that reduces SAV1 expression. With less SAV1, Hippo braking is reduced, allowing greater YAP activity. The goal is to encourage cardiomyocyte renewal, meaning replacement by the cells responsible for muscular contraction.[2]

The therapy does not inject YAP protein, deliver new stem cells, or cut out a gene with DNA-editing scissors. It seeks to lower production of a regulatory protein in targeted tissue. These distinctions matter because the mechanism influences what needs monitoring, how long an effect might persist, and how a treatment might be stopped if its activity became undesirable.

Delivery is also more involved than the phrase "single injection" suggests. The protocol uses a catheter procedure to administer treatment through the inner wall of the heart. Local delivery and a heart-muscle-directed expression system are intended to focus the effect. A one-time administration does not mean one ordinary intramuscular shot, or a biological effect that necessarily lasts only a few days.[2]

What the pig studies showed

The preclinical foundation includes a study in pigs given a heart attack, followed two weeks later by local delivery of an AAV-based treatment that reduced SAV1. Over approximately three months, treated animals showed improvements in pumping function, reduced scarring, and evidence consistent with heart muscle cell renewal. The work also examined blood-vessel changes in the injured region.[3]

Counting new cells requires a surprisingly awkward question: did a cell actually divide, or did it merely copy its DNA and stop there? Adult heart cells can do the latter. More genetic material does not automatically mean two useful contracting cells. Biology has once again declined our tidy accounting system. The study reported evidence consistent with cytokinesis, the physical separation step, alongside structural and functional measurements. Those distinctions strengthen the interpretation.[3]

That combination is more persuasive than a single molecular marker. Nevertheless, a pig experiment cannot establish how much new functional muscle a human heart will produce, how well it will integrate, or whether benefit will persist for years. Human ischemic heart failure often involves longstanding injury and multiple illnesses rather than a recent, experimentally timed infarction.

A later report examined rhythm recordings from the same animal research and found favorable changes in arrhythmic events after Hippo-pathway suppression. This was additional information from the earlier experiment, not an independent replication in another large group. It supports further investigation but cannot establish long-term electrical safety in people.[4]

New muscle must keep the rhythm

Next, suppose the cells really do divide. Wonderful. Now they must contract, connect electrically, survive under load, and fit into the ventricle's structure. A heart is a coordinated pump, so a roomful of individually energetic cells is not enough. An orchestra can acquire more musicians and still produce a spectacular racket if nobody follows the timing. Growth without organization could leave the heart less efficient or dangerously unstable.

A separate pig study provides a sobering example. An experimental microRNA treatment initially improved repair after a heart attack, but persistent, uncontrolled activity was later associated with fatal arrhythmias in many treated animals. This involved a different molecular strategy, not YAP101. It is relevant because it shows why early improvement in cardiac function cannot by itself establish the safety of a growth-promoting treatment.[5]

The lesson is to control location, degree, and duration of growth. Viral delivery can support prolonged expression, so researchers must understand how the biological response evolves after administration. Monitoring must look for electrical instability and unwanted tissue effects as well as improved pumping. An organ that beats continuously has little tolerance for enthusiastic but poorly coordinated reconstruction.

What SALVADOR-HF can tell us

The registered trial is a Phase 1, single-center, open-label dose-escalation study, with a planned enrollment of up to 24 participants. It focuses on medically stable adults with ischemic heart failure following a heart attack, reduced left-ventricular ejection fraction, and persistent symptoms despite established treatment. The eligibility criteria are narrower than "anyone with a weak heart."[2]

The principal outcomes concern adverse events, dose-limiting problems, and selection of a tolerable dose. Investigators also plan to assess cardiac imaging, exercise capacity, quality of life, hospitalizations, and rhythm-related outcomes. These additional measurements may reveal encouraging signals, but the small, uncontrolled study is not designed to deliver definitive evidence of clinical effectiveness.[2]

A small, uncontrolled trial also makes interpretation tricky. Patients receive other care, measurements vary, and selected participants may differ from the wider population. A favorable scan needs to be considered alongside symptoms and clinical events. Improved ejection fraction is not itself a photograph of newly grown muscle. The pump can improve for several reasons. We need evidence of the particular repair being claimed, however much we would like the hopeful interpretation to be right.

In a November 2025 announcement, the Texas Heart Institute reported that an initial cohort had been treated and that a safety review supported moving to the next cohort. That is a development milestone, not proof of repair or benefit. The registry record reviewed for this article had been updated in April 2025 and contained no posted results; its recruitment label should not be mistaken for a real-time enrollment confirmation.[2]

How you may be able to benefit

For someone with ischemic heart failure, the most useful immediate step is to review whether established treatment has been fully considered. Guidelines support several complementary medication classes for reduced-ejection-fraction heart failure, with choices adjusted to blood pressure, kidney function, potassium, and tolerability. Appropriate device therapy and assessment of coronary disease may also matter.[6]

Cardiac rehabilitation can help eligible patients with coronary disease regain activity safely and address ongoing risks. A recent review found benefits including fewer heart attacks and hospital admissions. Improving daily function through an established program remains valuable even while regenerative research explores whether lost tissue can eventually be replaced.[7]

Patients interested in a trial should ask their cardiologist about eligibility and verify current status with the study team. Important questions include the delivery procedure, duration of monitoring, unknown risks, and what happens if the treatment does not help. An early trial offers participation in an investigation; it cannot promise access to successful regeneration.

The pathway also does not establish a diet or supplement that safely activates YAP in the heart. Growth regulation is not a nutrient target to turn up indiscriminately. The experimental treatment depends on specific delivery and tissue targeting. No comparison of diets in this trial can identify an ideal menu for rebuilding heart muscle.

Preserving cardiac function could support independence and resilience with age, giving YAP101 a meaningful healthy-aging connection. It remains far from a demonstrated longevity treatment. The question now spans a growth signal, the behavior of individual cells, an electrically coordinated organ, and a person's ability to live well. Can those layers be persuaded to cooperate? That is what the human investigation begins to ask. The cells may be ready for encouragement; the claim of success needs to wait.

References

[1] Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98-102. doi:10.1126/science.1164680.

[2] ClinicalTrials.gov. SALVADOR-HF: A Phase 1 Study of YAP101 in Ischemic Heart Failure (NCT06831825). Registry last posted April 27, 2025; accessed October 10, 2026.

[3] Liu S, Li K, Wagner Florencio L, et al. Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction. Sci Transl Med. 2021;13(600):eabd6892. doi:10.1126/scitranslmed.abd6892.

[4] Zhang S, Liu S, Leach JP, et al. Gene Therapy Knockdown of Hippo Signaling Resolves Arrhythmic Events in Pigs After Myocardial Infarction. Circulation. 2022;146(20):1558-1560. doi:10.1161/circulationaha.122.059972.

[5] Gabisonia K, Prosdocimo G, Aquaro GD, et al. MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. Nature. 2019;569(7756):418-422. doi:10.1038/s41586-019-1191-6.

[6] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/cir.0000000000001063.

[7] Dibben G, de Vries FB, Faulkner J, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2026;9:CD001800. doi:10.1002/14651858.cd001800.pub5.